CRESCENT BIOPHARMA, INC. Deferred Rent Credit, Current
CRESCENT BIOPHARMA, INC. (CBIO) had Deferred Rent Credit, Current of $98.77 thousand as of 2018-12-31, per its 10-K filed 2020-02-28.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRentCreditCurrent · last filed 2020-02-28
- 2018-12-31: Deferred Rent Credit, Current $98.77K.
- 2018-09-30: Deferred Rent Credit, Current $92.65K.
- 2018-06-30: Deferred Rent Credit, Current $86.64K.
- 2018-03-31: Deferred Rent Credit, Current $82.02K.
| Period end | Deferred Rent Credit, Current |
|---|---|
| 2018-12-31 | $98.77K 10-K · filed 2020-02-28 |
| 2018-09-30 | $92.65K 10-Q · filed 2018-11-02 |
| 2018-06-30 | $86.64K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $82.02K 10-Q · filed 2018-05-03 |
| 2017-12-31 | $78.03K 10-K · filed 2019-03-06 |
| 2017-09-30 | $74.07K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $70.60K 10-Q · filed 2017-08-03 |
| 2017-03-31 | $70.60K 10-Q · filed 2017-05-08 |
| 2016-12-31 | $68.55K 10-K · filed 2018-03-06 |
| 2016-09-30 | $81.40K 10-Q · filed 2016-11-04 |
| 2016-06-30 | $81.40K 10-Q · filed 2016-08-04 |
| 2015-06-30 | $38.33K 10-Q · filed 2015-08-06 |
| 2015-03-31 | $67.97K 10-Q · filed 2015-05-05 |
| 2014-12-31 | $97.01K 10-K · filed 2016-02-29 |
| 2014-09-30 | $115.05K 10-Q · filed 2014-10-31 |
| 2014-06-30 | $111.40K 10-Q · filed 2014-07-31 |
| 2014-03-31 | $107.69K 10-Q · filed 2014-05-09 |
| 2013-12-31 | $104.19K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |